Cambridge Investment Research Advisors’s Axsome Therapeutics AXSM Stock Holding History

Cambridge Investment Research Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$348K	Sell	1,421 -1,291	-48%	-$280K	﹤0.01%	3313
2026 Q1	$458K	Sell	2,712 -17	-0.6%	-$2.94K	﹤0.01%	2881
2025 Q4	$498K	Buy	+2,729	New	+$381K	﹤0.01%	2720
2022 Q2	–	Sell	-9,525	Closed	-$394K	–	3055
2022 Q1	$394K	Sell	9,525 -1,915	-17%	-$59.4K	﹤0.01%	2305
2021 Q4	$432K	Hold	11,440	–	–	﹤0.01%	2226
2021 Q3	$377K	Buy	11,440 +3,905	+52%	+$152K	﹤0.01%	2266
2021 Q2	$508K	Sell	7,535 -2,115	-22%	-$127K	﹤0.01%	2048
2021 Q1	$546K	Buy	+9,650	New	+$679K	﹤0.01%	1838
2020 Q1	–	Sell	-2,603	Closed	-$269K	–	2284
2019 Q4	$269K	Sell	2,603 -8,072	-76%	-$326K	﹤0.01%	1977
2019 Q3	$216K	Sell	10,675 -225	-2%	-$5.78K	﹤0.01%	2060
2019 Q2	$281K	Buy	+10,900	New	+$218K	﹤0.01%	1776

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cambridge Investment Research Advisors's AXSM Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Axsome Therapeutics (AXSM) stake by 48% in Q2 2026, selling an estimated $280K and leaving 1,421 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #3313.

Cambridge Investment Research Advisors first reported a position in AXSM in Q2 2019 and has held it in 11 quarters since. The position peaked at $546K in Q1 2021. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Cambridge Investment Research Advisors held 1,421 shares of Axsome Therapeutics worth $348K as of Q2 2026.
Cambridge Investment Research Advisors sold 1,291 Axsome Therapeutics shares in Q2 2026, an estimated $280K.
Axsome Therapeutics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3313 holding.
Cambridge Investment Research Advisors first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 11 quarters since.
Cambridge Investment Research Advisors's Axsome Therapeutics position peaked at $546K in Q1 2021.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.